AU2008257322B2 - Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease - Google Patents
Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease Download PDFInfo
- Publication number
- AU2008257322B2 AU2008257322B2 AU2008257322A AU2008257322A AU2008257322B2 AU 2008257322 B2 AU2008257322 B2 AU 2008257322B2 AU 2008257322 A AU2008257322 A AU 2008257322A AU 2008257322 A AU2008257322 A AU 2008257322A AU 2008257322 B2 AU2008257322 B2 AU 2008257322B2
- Authority
- AU
- Australia
- Prior art keywords
- dichloro
- cyclopropylmethoxy
- carboxamide
- methoxy
- oxidopyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims description 14
- BRUDLLFMCVQZFT-UHFFFAOYSA-N COC1=CN=C(C(=O)NC=2C(=C[N+]([O-])=CC=2Cl)Cl)C=C1OCC1CC1 Chemical compound COC1=CN=C(C(=O)NC=2C(=C[N+]([O-])=CC=2Cl)Cl)C=C1OCC1CC1 BRUDLLFMCVQZFT-UHFFFAOYSA-N 0.000 title claims description 13
- 208000019430 Motor disease Diseases 0.000 title claims description 13
- 238000000034 method Methods 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000000095 emetic effect Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 7
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 206010038776 Retching Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000004771 dopaminergic neurodegeneration Effects 0.000 claims description 4
- 206010001541 Akinesia Diseases 0.000 claims description 3
- 206010006100 Bradykinesia Diseases 0.000 claims description 3
- 208000006083 Hypokinesia Diseases 0.000 claims description 3
- 208000002740 Muscle Rigidity Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000001144 postural effect Effects 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 210000005070 sphincter Anatomy 0.000 claims description 3
- 208000019505 Deglutition disease Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- XTXNLDRWBOSUAZ-UHFFFAOYSA-N n-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-5-methoxypyridine-2-carboxamide Chemical compound N1=CC(OC)=CC=C1C(=O)N(C=1C(=C[N+]([O-])=CC=1Cl)Cl)OCC1CC1 XTXNLDRWBOSUAZ-UHFFFAOYSA-N 0.000 claims 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 241000282339 Mustela Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- HJORMJIFDVBMOB-GFCCVEGCSA-N (+/-)-Rolipram Chemical compound COC1=CC=C([C@@H]2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-GFCCVEGCSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- OVHHNKPYYVQCLN-LJQANCHMSA-N (2r)-4-(6-chloronaphthalen-2-yl)sulfonyl-1-(5-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)piperazine-2-carboxamide Chemical compound C1=C(Cl)C=CC2=CC(S(=O)(=O)N3CCN([C@H](C3)C(N)=O)C(=O)C3=NC=4CCN(CC=4S3)C)=CC=C21 OVHHNKPYYVQCLN-LJQANCHMSA-N 0.000 description 2
- RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 2
- WCPJRIMIWAYBEA-UHFFFAOYSA-N 3-methoxypyridine-2-carboxamide Chemical compound COC1=CC=CN=C1C(N)=O WCPJRIMIWAYBEA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000028436 dopamine uptake Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002895 emetic Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- -1 4-cyclopropylmethoxy-N-(3,5 dichloro-1-oxidopyridin-4-yl)-5-( ethoxy)pyridine-2-carboxamide Chemical compound 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DGCAIDSMOQFYJD-UHFFFAOYSA-N C1(CC1)COC=1C(=NC=C(C1)OC)C(=O)NC1=C(C=[N+](C=C1Cl)[O-])Cl Chemical compound C1(CC1)COC=1C(=NC=C(C1)OC)C(=O)NC1=C(C=[N+](C=C1Cl)[O-])Cl DGCAIDSMOQFYJD-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- LVQACCHCDMXDDW-UHFFFAOYSA-N COc1ccc(nc1)C(=O)Nc1c(Cl)c[n+]([O-])cc1Cl Chemical compound COc1ccc(nc1)C(=O)Nc1c(Cl)c[n+]([O-])cc1Cl LVQACCHCDMXDDW-UHFFFAOYSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0702853A FR2915100B1 (fr) | 2007-04-19 | 2007-04-19 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson |
| FR0702853 | 2007-04-19 | ||
| PCT/FR2008/000534 WO2008145841A1 (fr) | 2007-04-19 | 2008-04-16 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008257322A1 AU2008257322A1 (en) | 2008-12-04 |
| AU2008257322B2 true AU2008257322B2 (en) | 2013-06-13 |
Family
ID=38712405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008257322A Ceased AU2008257322B2 (en) | 2007-04-19 | 2008-04-16 | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease |
Country Status (33)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104955808A (zh) * | 2012-11-28 | 2015-09-30 | 赛诺菲 | 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型 |
| US9624100B2 (en) | 2014-06-12 | 2017-04-18 | Apple Inc. | Micro pick up array pivot mount with integrated strain sensing elements |
| WO2025080415A1 (en) * | 2023-10-12 | 2025-04-17 | Alto Neuroscience, Inc. | Treatment of neuropsychiatric disorders with tilivapram |
| WO2025079694A1 (ja) * | 2023-10-12 | 2025-04-17 | 株式会社 メドレックス | 経皮吸収組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995004045A1 (en) * | 1993-07-28 | 1995-02-09 | Rhone-Poulenc Rorer Limited | Compounds as pde iv and tnf inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193926A (en) * | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| ATE290002T1 (de) * | 1999-12-23 | 2005-03-15 | Icos Corp | Cyclische amp spezifische phosphodiesterase inhibitoren |
| EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
| AU2003281219A1 (en) * | 2002-07-02 | 2004-01-23 | Bernard Cote | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| AU2004220456B2 (en) * | 2003-03-12 | 2010-10-14 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
| WO2006135828A2 (en) * | 2005-06-10 | 2006-12-21 | Memory Pharmaceuticals Corporation | Trisubstituted amines as phosphodiesterase 4 inhibitors |
| US20070021451A1 (en) * | 2005-07-20 | 2007-01-25 | Hamamatsu University School Of Medicine | Method for preventing or treating neurologic damage after spinal cord injury |
-
2007
- 2007-04-19 FR FR0702853A patent/FR2915100B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-15 PA PA20088776801A patent/PA8776801A1/es unknown
- 2008-04-16 CN CN2008800126498A patent/CN101663035B/zh not_active Expired - Fee Related
- 2008-04-16 EP EP08787963A patent/EP2146714B1/fr active Active
- 2008-04-16 MY MYPI20094343A patent/MY148092A/en unknown
- 2008-04-16 KR KR1020147033000A patent/KR20150004885A/ko not_active Ceased
- 2008-04-16 CA CA2684174A patent/CA2684174C/fr not_active Expired - Fee Related
- 2008-04-16 BR BRPI0810444A patent/BRPI0810444A2/pt not_active IP Right Cessation
- 2008-04-16 SI SI200830357T patent/SI2146714T1/sl unknown
- 2008-04-16 PT PT08787963T patent/PT2146714E/pt unknown
- 2008-04-16 MX MX2009011284A patent/MX2009011284A/es active IP Right Grant
- 2008-04-16 AT AT08787963T patent/ATE513548T1/de active
- 2008-04-16 RS RS20110358A patent/RS51869B/sr unknown
- 2008-04-16 DK DK08787963.1T patent/DK2146714T3/da active
- 2008-04-16 JP JP2010503549A patent/JP5386478B2/ja not_active Expired - Fee Related
- 2008-04-16 KR KR1020097021593A patent/KR101503942B1/ko not_active Expired - Fee Related
- 2008-04-16 ME MEP-2009-299A patent/ME00935B/me unknown
- 2008-04-16 PL PL08787963T patent/PL2146714T3/pl unknown
- 2008-04-16 NZ NZ580482A patent/NZ580482A/en not_active IP Right Cessation
- 2008-04-16 WO PCT/FR2008/000534 patent/WO2008145841A1/fr not_active Ceased
- 2008-04-16 AU AU2008257322A patent/AU2008257322B2/en not_active Ceased
- 2008-04-16 EA EA200970970A patent/EA019194B1/ru not_active IP Right Cessation
- 2008-04-16 HR HR20110666T patent/HRP20110666T1/hr unknown
- 2008-04-16 ES ES08787963T patent/ES2367408T3/es active Active
- 2008-04-17 TW TW097113997A patent/TWI439269B/zh not_active IP Right Cessation
- 2008-04-17 JO JO2008182A patent/JO2678B1/en active
- 2008-04-18 CL CL2008001136A patent/CL2008001136A1/es unknown
- 2008-04-18 UY UY31035A patent/UY31035A1/es not_active Application Discontinuation
- 2008-04-18 AR ARP080101602A patent/AR066108A1/es unknown
-
2009
- 2009-10-05 US US12/573,326 patent/US20100130554A1/en not_active Abandoned
- 2009-10-11 IL IL201448A patent/IL201448A/en not_active IP Right Cessation
- 2009-10-16 ZA ZA2009/07251A patent/ZA200907251B/en unknown
- 2009-11-10 MA MA32333A patent/MA31367B1/fr unknown
-
2011
- 2011-09-15 CY CY20111100887T patent/CY1111840T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995004045A1 (en) * | 1993-07-28 | 1995-02-09 | Rhone-Poulenc Rorer Limited | Compounds as pde iv and tnf inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008257322B2 (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease | |
| US8592443B2 (en) | Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas | |
| AU2008257319B2 (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas | |
| HK1141725B (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament in the treatment of motor disorders related to parkinson's disease | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| HK1141724B (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas | |
| HK1142000B (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas | |
| JPH02231421A (ja) | 記憶障害改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)P YRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |